• Explore /
  • Poster
  • / CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.

CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.

Abstract Poster

Authors

Ronan Kelly

Ronan Joseph Kelly

Johns Hopkins School of Medicine, Baltimore, MD

Ronan Joseph Kelly , Albert C. Lockhart , Derek J. Jonker , Bohuslav Melichar , Thierry Andre , Ian Chau , Stephen John Clarke , James M. Cleary , Yuichiro Doki , Fabio Andre Franke , Yuko Kitagawa , Christophe Mariette , Paola Catherine Montenegro , Enrique Luis Roca , Marika Ciprotti , Markus Moehler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02743494

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract TPS212)

DOI

10.1200/JCO.2017.35.4_suppl.TPS212

Abstract #

TPS212

Poster Bd #

N16

Abstract Disclosures

Similar Posters

First Author: Ronan Joseph Kelly

First Author: Yelena Yuriy Janjigian

First Author: Nick Pavlakis

First Author: Kynan Feeney